Symptom Management and Team Care

Because ALSP is a complex disease that affects many different parts of the brain, there is currently no single proven disease-modifying treatment ^[1]. Instead, the standard of care is multidisciplinary management—a team of specialists working together to address each symptom as it arises ^[2]. The goal is to maximize your quality of life, maintain your independence for as long as possible, and support you and your family ^[2][3].

Building Your Care Team

A multidisciplinary team ensures that every aspect of the disease is being monitored. Your team should ideally include:

• Neurologist/Neurogeneticist: To coordinate overall care, monitor disease progression, and manage physical symptoms like seizures or movement issues ^[1][4].
• Neuropsychiatrist: To treat behavioral changes, such as apathy (loss of interest), depression, or anxiety, which are very common in ALSP ^[5].
• Physical (PT) and Occupational Therapist (OT): To help with mobility, prevent falls, and suggest home modifications or assistive devices (like walkers) to keep you safe ^[6][7].
• Speech-Language Pathologist (SLP): Crucial for evaluating and managing aphasia (communication trouble) and dysphagia (swallowing difficulty) ^[8][9].
• Social Worker / Palliative Care: To help you navigate insurance, disability benefits, and local support resources for you and your caregivers ^[2]. Palliative care is an extra layer of support focused on comfort and symptom relief that can be introduced at any stage alongside standard treatments.

Managing Specific Symptoms

While we cannot yet stop the underlying disease process, many of the symptoms can be managed with existing medical tools:

Movement and “Parkinsonism”

The stiffness, slowness, and tremors seen in ALSP are often called parkinsonism ^[10]. Some doctors may try an individualized, monitored trial of medications typically used for Parkinson’s disease, such as levodopa ^[11]. However, their effectiveness in ALSP varies greatly, and they require careful discussion of adverse effects. PT is essential here to maintain flexibility and strength ^[6].

Cognitive and Behavioral Health

For the cognitive decline, your doctor may consider “off-label” trials of medications used in other dementias, though their benefit in ALSP is unproven and must be carefully monitored ^[1]. Managing the environment—keeping a predictable routine and reducing overstimulation—can also help reduce anxiety and behavioral outbursts ^[5].

Swallowing and Communication

Worsening dysphagia (swallowing trouble) is a significant risk in ALSP because it can lead to aspiration pneumonia (food or liquid entering the lungs) ^[9]. Regular evaluations by an SLP are vital. They can recommend communication aids (like tablet-based “talkers”) to help you express your needs. If swallowing is unsafe, an SLP may recommend diet texture changes, such as thickened liquids ^[8][9]. Note: Thickening liquids should only be done following a formal SLP assessment, as it can worsen hydration or be inappropriate for certain swallowing patterns, and it does not eliminate aspiration risk.

Investigational and Emerging Therapies

Researchers are working on experimental therapies that aim to address the affected CSF1R signaling in the brain.

• Iluzanebart (VGL101): This is an investigational antibody currently in clinical development ^[12]. It targets a different protein on the microglia (called TREM2) to try to induce microglial signaling ^[12]. While early phase-1 studies evaluated its safety in healthy volunteers, tolerability in healthy individuals does not establish safety or clinical benefit in people with ALSP ^[13][14]. It is strictly an investigational agent and its efficacy is still being studied. Before considering any clinical trial, you should review the trial’s exact status (phase, recruitment, placebo use) on a registry like ClinicalTrials.gov.
• HSCT (Stem Cell Transplant): In some specific cases, doctors at expert centers may consider an allogeneic Hematopoietic Stem Cell Transplant ^[4]. The theoretical goal is to replace the failing immune system with donor cells, hoping they can support the brain’s white matter ^[15]. This is an investigational, extremely high-risk procedure that may be associated with better outcomes when considered very early in the disease course, but carries substantial risks of mortality and severe complications ^[16][15].

It is important to discuss these options with a specialist at an experienced Leukodystrophy Center, as they can help you weigh the risks and benefits based on your specific stage of the disease and access to current clinical trials ^[4].